About

Pegfilgrastim is a pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF). It functions by stimulating the production, maturation, and release of neutrophils from the bone marrow. Neutrophils are a type of white blood cell crucial for fighting bacterial infections. This medication is primarily used to reduce the incidence of febrile neutropenia, a serious complication of myelosuppressive chemotherapy that can lead to life-threatening infections.

By accelerating neutrophil recovery, pegfilgrastim helps maintain chemotherapy schedules, reduces the risk of infection, and improves patient outcomes in oncology settings. Its pegylated formulation allows for a single dose per chemotherapy cycle, offering convenience and sustained action.

Uses

Reduce incidence of febrile neutropenia
Supportive care during myelosuppressive chemotherapy
Mobilization of hematopoietic stem cells
Severe chronic neutropenia (off-label for some G-CSFs)

Directions For Use

Administer as a single subcutaneous injection once per chemotherapy cycle, at least 24 hours after chemotherapy. Do not administer within 14 days before the next chemotherapy dose.

Benefits

Reduces risk of life-threatening infections.
Prevents chemotherapy-induced neutropenia.
Allows for on-schedule chemotherapy cycles.
Improves patient safety during cancer treatment.
Convenient single dose per cycle.
Stimulates white blood cell production.

Side Effects

Bone pain
Musculoskeletal pain
Nausea
Fatigue
Headache
Injection site reactions
Splenic rupture (rare, serious)
Acute respiratory distress syndrome (rare)
Glomerulonephritis (rare)
Leukocytosis
Thrombocytopenia
Allergic reactions

Safety Measures

Alcohol - No direct interaction with alcohol. However, alcohol should be consumed in moderation, especially during chemotherapy.
Pregnancy - Use only if clearly needed and potential benefits outweigh risks. Consult a doctor.
Breastfeeding - Unknown if excreted in human milk. Exercise caution; consult a healthcare provider.
Liver - No specific dose adjustment is typically required for liver impairment.
Kidney - No specific dose adjustment is typically required for kidney impairment.
Lung - Use with caution in patients with pre-existing lung conditions due to rare risk of acute respiratory distress syndrome (ARDS) or interstitial lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.

Shipping & Location